Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Route of Administration: intravenous infusion Unit Dose Strength: 5.02 x10\^13 Vg/ml in a volume of 1 mL/vial”In the company’s words, NCT07830563 on ClinicalTrials.gov
- Tested for
- Congenital Myasthenia Syndrome
- Main trialPhase 1
- “This study is evaluating the safety and potential effects of AMP-101 in people with DOK7 Congenital Myasthenia Syndrome (CMS). Participants will receive a single dose of the study treatment and will be monitored to assess their health and response to treatment. Approximately 4 participants are expected to take part in the study.”In the company’s words, NCT07830563 on ClinicalTrials.gov
Other drugs for Congenital Myasthenia Syndrome
- Adimanebartargenx · Phase 3
Coming up1
- 1 Oct 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 1 Oct 2028 | Evaluating the Safety and Effects of AMP-101 in People With DOK7 Congenital Myasthenia Syndrome |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026